First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER

Oncologist

Volumn 18, Issue 5, 2013, Pages 501-510

  Tripathy, Debu ^a   Kaufman, Peter A ^b   Brufsky, Adam M ^c   Mayer, Musa ^d   Yood, Marianne Ulcickas ^e,f   Yoo, Bongin ^g   Quah, Cheng ^g   Yardley, Denise ^h   Rugo, Hope S ⁱ  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Patient Advocate   (United States)

^e EpiSource LLC   (United States)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^g GENENTECH INC   (United States)

^h SARAH CANNON RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast cancer; HER2; Hormone receptor; Metastatic; Trastuzumab; Treatment

Indexed keywords

AROMATASE INHIBITOR; FULVESTRANT; GONADORELIN; TAMOXIFEN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER HORMONE THERAPY; CHEMOTHERAPY; COHORT ANALYSIS; DEATH; DISEASE COURSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RISK; SENSITIVITY ANALYSIS; TREATMENT PLANNING; TUMOR GROWTH;

BREAST CANCER; HER2; HORMONE RECEPTOR; METASTATIC; TRASTUZUMAB; TREATMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84878192141     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2012-0414     Document Type: Article

References (23)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353:1659-1672.
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
4. Brufsky A, Lembersky B, Schiffman K et al. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer. Clin Breast Cancer 2005; 6:247-252.
5. Todorovic-Rakovic N, Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D. Cross-talkbetweenERandHER2 in breastcarcinoma. ArchOncol2006;14:146-150.
6. Sabnis G, Brodie A. Understanding resistance to endocrine agents: Molecular mechanisms and potential for intervention. Clin Breast Cancer 2010;10: E6-E15.
7. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. AnnuRevMed 2011;62: 233-247.
8. Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012; 366:520-529.
9. Chu QS, Cianfrocca ME, Goldstein LJ et al. A phase I and pharmacokinetic study of lapatinib in combination withletrozoleinpatientswithadvancedcancer. ClinCancerRes 2008; 14:4484-4490.
10. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol 2009;20:993-999.
11. Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAn- DEM study. J Clin Oncol 2009;27:5529-5537.
12. Johnston S, Pippen J Jr., Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-5546.
13. Goldenberg GJ, Froese EK. Antagonism of the cytocidal activity and uptake of melphalan by tamoxifen in human breast cancer cells in vitro. Biochem Pharmacol 1985;34:763-770.
14. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 1989;7:710-717.
15. Hug V, Hortobagyi GN, Drewinko B et al. Tamoxifen- citrate counteracts the antitumor effects of cytotoxicdrugsin vitro. J ClinOncol1985;3:1672-1677.
16. Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 1983;43:3998-4006.
17. Albain KS, Barlow WE, Shak S et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with nodepositive, oestrogen-receptor-positive breast cancer on chemotherapy: A retrospective analysis of a randomised trial. Lancet Oncol 2010;11:55-65.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn 1958;53:457-481.
19. Gluck S, Arteaga CL, Osborne CK. Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clin Cancer Res 2011;17:5559-5561.
20. Pritchard KI. Combining endocrine agents with chemotherapy: Which patients and what sequence? Cancer 2008;112(3 suppl):718-722.
21. Albain K, Barlow W, Ravdin P et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet 2009;374: 2055-2063.
22. Montemurro F, Rossi V -CR, Cossu Rocca M et al. Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. Cancer 2012;118: 17-26.
23. Rimawi MF, Mayer IA, Forero A et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 2013; April 8 [E-pub ahead of print].